Philip Sutera, Matthew P Deek, Rebecca A Deek, Ozan Cem Guler, Pervin Hurmuz, Mehmet Reyhan, Steven Rowe, Noura Radwan, Shirl Dipasquale, William T Hrinivich, Kathryn Lowe, Lei Ren, Biren Saraiya, Ronald Ennis, Lara Hathout, Tina Mayer, Theodore L Deweese, Daniel Y Song, Ana Kiess, Ezgi Oymak, Kenneth Pienta, Felix Feng, Martin Pomper, Gokhan Ozyigit, Phuoc T Tran, Cem Onal, Ryan M Phillips
PURPOSE: Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease, and PSMA response has been proposed as a biomarker for treatment response. Herein, we identify and validate a PSMA-PET biomarker for metastasis-free survival (MFS) following MDT in omCSPC. METHODS AND MATERIALS: We performed an international multi-institutional retrospective study of patients with omCSPC, defined as ≤3 lesions, treated with metastasis-directed stereotactic ablative radiation who underwent PSMA-PET/computed tomography (CT) before and after (median, 6...
July 2024: Advances in Radiation Oncology